DrugPatentWatch Database Preview

Details for Patent: 8,791,154

« Back to Dashboard

Which drugs does patent 8,791,154 protect, and when does it expire?

Patent 8,791,154 protects PAZEO and is included in one NDA.

This patent has twenty-seven patent family members in seventeen countries.

Summary for Patent: 8,791,154

Title:	High concentration olopatadine ophthalmic composition
Abstract:	The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.
Inventor(s):	Gamache; Daniel A. (Arlington, TX), Alani; Laman (Fort Worth, TX), Ghosh; Malay (Fort Worth, TX), Galan; Francisco Javier (Barcelona, ES), Perdiguer; N ria Carreras (Barcelona, ES), Singh; Onkar N. (Arlington, TX)
Assignee:	Alcon Research, Ltd. (Fort Worth, TX)
Application Number:	13/475,607
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,791,154
Patent Claim Types: see list of patent claims	Use; Formulation; Compound;

Drugs Protected by US Patent 8,791,154

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Novartis Pharms Corp	PAZEO	olopatadine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	206276-001	Jan 30, 2015		RX	Yes	Yes			Y			TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS

Non-Orange Book US Patents Family Members for Patent 8,791,154

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
9,533,053	High concentration olopatadine ophthalmic composition

International Family Members for US Patent 8,791,154

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3045172
Spain	2587869
South Korea	101689924
Hong Kong	1194971